Kornimate/medical-research-clean huggingface dataset:
meritni - mindray-hs-ctni assay: analytical and clinical evaluation for the diagnosis and risk assessment of myocardial infarction.

Conditions: Acute Myocardial Infarction; Acute Coronary Syndrome

Summary: the mindray high sensitivity troponin-i measurement system is an in vitro diagnostic test for the quantitative determination of high sensitivity cardiac troponin i (hs-ctni) in human serum or plasma. the mindray high sensitivity troponin-i measurement system is to be used as an aid in the diagnosis and rule out of acute myocardial infarction (ami).

study purpose/objective: * determine the sex-specific 99th percentile upper reference limits (urls) for the mindray hs-ctni assay using the cl-1200i instrument. * method comparison across the dynamic range of ctni concentrations between the mindray hs-ctni assay and the abbott alinity hs-tni assay used in clinical practice at hennepin healthcare/hennepin county medical center. * evaluate the clinical performance of the mindray hs- ctni measuring system for the diagnosis of myocardial infarction (mi), for early rule out mi and myocardial injury, and assessment of 30-day safety outcomes in patients presenting to the emergency department (ed) in whom serial ctni measurements (0h, 2h, 4h, 6h) are obtained on clinical indication at hennepin healthcare / hennepin county medical center (minneapolis, mn usa) to rule-in and rule-out mi.

Eligibility criteria:
inclusion criteria: 1. presents to the ed, or ambulatory care center equivalent, with signs or symptoms suspicious of a possible acs/ischemic event. 2. baseline ctn-i measurement and one additional ctn-i measurement at two hours after the first measurement. 3. at least one 12-lead electrocardiogram exclusion criteria: 1. less than 21 years old 2. pregnancy 3. trauma 4. declines to participate or has indicated that their blood/ medical information cannot be used for investigational purposes 5. did not present through the ed 6. transferred from an outside hospital or clinic 7. has already been enrolled in the study

Keywords: cardiac troponin acute myocardial injury acute myocardial infarction high-sensitivity cardiac troponin i mindray mindray bio-medical cardiac troponin i reference range abbott alinity type 1 myocardial infarction type 2 myocardial infarction risk outcomes assessment
feasibility study to evaluate the role of a novel device in childbirth

Conditions: Surgical Item, Retained; Childbirth

Summary: accidentally retained surgical items or swabs are well-recognised errors that result in adverse consequences for patients. this error is one of the commonest "never events" - patient safety incidents that are considered preventable. although uncommon, these incidents can have devastating consequences. retained surgical items have 70% re-interventions, reaching 80% morbidity and 35% mortality. swabs or sponges are like small towels that soak up blood and body fluids so that the surgeon can visualise the operating area effectively. swabs are used in all areas of surgery which include operations on the tummy, chest, limbs. they are also used in the vagina during childbirth, to assess for tears and to minimise blood oozing from the vagina. the common risk factors for this error are out of hours surgical or childbirth procedures, multiple handovers in the care of the patient, raised bmi (body mass index) and unplanned change to the operative intervention. as the name suggests, a 'never event' should never happen in the first place. never. unfortunately, this is not the case. incidents involving surgical swabs being left behind, particularly during a caesarean section or a perineal repair following a vaginal birth, are still happening despite over 100 years of institutional awareness of the problem and tentative solutions being implemented in clinical practice. never-event incidents involving retained surgical swabs are a widespread problem affecting healthcare systems worldwide. it is therefore reasonable to ask the question: why are surgical swabs being left behind and what can be done to prevent this from happening?


Eligibility criteria:
inclusion criteria: * midwifery lead and consultant lead patient older than 18 years. * consented to participation after an informed choice. exclusion criteria: • under 18 years of age antenatal (before labour): * patients who have a high risk of expected/unexpected maternal, fetal or neonatal deterioration such that during birth, the focus of attention would be towards safe patient care and observation required for using the swab-counter device system would not be possible such as : * patients who are seriously unwell and require high dependency care. * maternal cardiac conditions * severe pre-eclampsia * fetal anomalies where neonatal deterioration is expected (these will be relatively rare conditions where the doctor/midwife would decide to not recruit the patient) intrapartum and postpartum factors: * patient having an emergency caesarean section instead of a vaginal birth due to maternal or fetal indication. * eclampsia (seizure/fitting in labour or after delivery) * maternal cardiac conditions requiring high dependency care * severe sepsis requiring high dependency care * fetal anomalies where neonatal deterioration is expected
assessment of the anesthetic effect on the activity of immune cell in patient with colon cancer

Conditions: Colon Cancer

Summary: anesthetics agents has variety inflammation during the cancer surgery. this perioperative inflammation can influence to cancer metastasis or recurrence. the purpose of this study is to prove the variation of immune cell activity between preoperative and postoperative period.

the patients were allocated randomly to receive propofol or sevoflurane. also, a total of 18ml of blood sample was obtained for total 3 times in consecutive order. 1. immediate before anesthesia induction 2. postoperative 1 hours 3. postoperative 24 hours serum in blood will be obtained and activity of helper t cell, natural killer cell and level of serum cytokine will be evaluated by flow cytometry or enzyme-linked immunosorbent assay

Eligibility criteria:
inclusion criteria: * patient who was planned to undergo colon cancer surgery. exclusion criteria: * age \< 20 years old * history of hypersensitivity reaction in propofol or sevoflurane * history of previous cancer * patient with ongoing inflammation
study of the proteome and cytokines during inflammatory syndromes of different etiologies.

Conditions: Inflammatory Disease

Summary: the hypotheses of our research are based on the fact that various pathological states, infection, cancer, inflammatory disease, can induce an inflammatory syndrome, through different pathways, even though the clinical presentation can be identical. the identification of biological markers specific to an etiology would therefore allow a faster diagnosis and improve care for patients. we thus took an interest in the three groups of diseases most frequently responsible for an inflammatory syndrome, infections, cancers and auto-immune diseases. to achieve this, various methods will be used.


Eligibility criteria:
inclusion criteria: patients presenting an inflammatory syndrome, defined by elevated c-reactive protein (crp\>50mg/l), whose etiology is related to infection, cancer or an inflammatory disease. * patients not on treatment (corticoids, immunosuppressive drugs) during the 7 days preceding inclusion * age: 18-90 years * patients covered by the national health insurance agency * signed written informed consent form exclusion criteria: * - any patient not meeting the inclusion criteria * pregnant patients
word-retrieval treatment for aphasia: semantic feature analysis

Conditions: Aphasia; Language Disorders; Speech Disorders

Summary: the purpose of this investigation is to further develop and test a treatment for word-finding problems in aphasia. the treatment is designed to strengthen meaning associations within categories of words (e.g., animals, tools, fruits). the treatment is also designed to be used as a search strategy in instances of word-finding difficulty. the study was devised to evaluate the extent to which treatment increases the ability to recall trained, as well as untrained, words.

the purpose of the proposed research is to examine the effects of a semantically-oriented treatment on word retrieval in persons with aphasia. the planned investigations are designed to further the development of semantic feature training so that it may serve as not only a mechanism for improving disrupted lexical semantic processing, but also as a compensatory strategy during word retrieval failures. the proposed research will also address the issue of exemplar typicality (kiran \& thompson, 2003) by examining the effects of training typical versus atypical exemplars of various categories with individuals with different types of aphasia. a series of 24 single subject experimental designs will be conducted in the context of a group design to address the following experimental questions: * will training atypical examples of living and artifact noun categories using semantic feature training result in a significantly different outcome\* than training typical examples of living and artifact noun categories? * will training of one category of nouns using semantic feature training result in improved retrieval of untrained categories of nouns? * will effects of semantic feature training vary across aphasia types? * will semantic feature training result in increased production of content during discourse? * will generalization to untrained typical examples vary across generalization lists that are repeatedly exposed and those that are limited in exposure? (i.e., does repeated exposure appear to contribute to generalization?) * outcome measure will reflect acquisition, response generalization within category, and response generalization across category effects of treatment.

Eligibility criteria:
inclusion criteria: * diagnosis of wernicke's, broca's, or conduction aphasia with significant word-retrieval deficits * at least 6 months post-onset of single, left-hemisphere stroke * minimum of high-school education * visual and auditory acuity sufficient for experimental tasks * nonverbal intelligence within normal limits exclusion criteria: * diagnosed mental illness other than depression * neurological condition other than that which resulted in aphasia * history of alcohol or substance abuse * non-native english speaker * premorbid history of speech/language disorder

Keywords: aphasia language therapy rehabilitation of speech and language disorders speech-language pathology
metabolic alkalosis in heart failure

Conditions: Heart Failure; Metabolic Alkalosis; Diuretics Drug Reactions; Decompensated Heart Failure; Acute Heart Failure

Summary: metabolic alkalosis (ma) is the most common acid-base disorder and when it's severe it can have effects on cellular function and contribute to an increase in mortality. ma is a common complication of heart failure (hf) especially when patients are treated with diuretics, but few studies have analyzed the prevalence of acid-base disorders in patients with hf. all these studies have shown that ma is more common in patients with hf in more advanced stages and that the use of diuretics increases the prevalence of ma. the study hypothesis, based on clinical experience and the few data that exist in the scientific literature, is that ma is a frequent analytical disorder in patients admitted for decompensated hf and that its presence entails a worse short-term vital prognosis. the alcalotic study is an observational cohort and prospective study. the main objectives of the study are the following: 1. to determine the prevalence of ma in patients admitted for decompensated hf 2. to analyze if there are differences in patients admitted for hf according to the presence of ma on admission 3. to determine if the presence of ma has an influence on the short-term prognosis in patients admitted for decompensated hf


Eligibility criteria:
inclusion criteria: * patient admitted for decompensated hf (main admission diagnosis), who meet the diagnostic criteria of the 2016 european hf guidelines and who sign the informed consent to participate in the study * patients must give their written consent to participate in the study exclusion criteria: * patients whose main reason for admission is not decompensated hf. those patients who are admitted for another reason and who also have decompensated hf secondarily cannot be included * patients who do not strictly meet the diagnostic criteria for hf of the european hf guidelines. * patients for whom analytical values are not available in relation to acid-base balance at the time of admission * patients with a pathological history that can clearly justify metabolic alkalosis, such as primary or secondary hyperaldosterism * patients who were taking sodium bicarbonate prior to admission * patients with factors present at admission that may justify the presence of metabolis alkalosis: vomiting, diarrea, etc. * patients who do not give their consent to participate in the study

Keywords: metabolic alkasosis heart failure
predictors of early chest infection in acute ischemic stroke

Conditions: Acute Ischemic Stroke; Pneumonia

Summary: pneumonia is a frequent complication of acute stroke and is associated with increased mortality and long-term impairment in the affected subjects. in previous studies, a number of clinical (e.g., dysphagia, severe neurological impairment, mechanical ventilation), radiological (e.g., large infarctions in the territory of middle cerebral artery, insular infarction) and biochemical (e.g., increased serum levels of c-reactive protein, decreased levels of cd4+ t-lymphocytes) findings have been reported as risk factors of stroke-related chest infection. the present study (precast) aims to identify a small set out of these previously described risk factors that can predict stroke-related pneumonia with high sensitivity and specificity.


Eligibility criteria:
inclusion criteria: * acute ischemic stroke * admission to the neurological intensive care unit or stroke unit within 24 hours after stroke onset * clearly assessed brain lesion location exclusion criteria: * previous large (non-lacunar) stroke * chest infection present already on hospital admission * mechanical ventilation already on day 1 or 2 after hospital admission * treatment with immunosuppressive drugs

Keywords: acute stroke ischemic stroke pneumonia chest infection brain lesion lesion topology dysphagia sympathetic activation immunosuppression
anti-pd-1/pd-l1 combined with anti-angiogenic agents as first-line treatment for unresectable hcc

Conditions: Unresectable Hepatocellular Carcinoma

Summary: this is a multicenter, randomized, open-label clinical study to evaluate the efficacy and safety of adebrelimab plus apatinib (cohort 1), or adebrelimab plus bevacizumab (cohort 2), or camrelizumab plus apatinib (cohort 3) as first-line treatment of unresectable hcc.


Eligibility criteria:
inclusion criteria: * locally advanced or metastatic and/or unresectable hepatocellular carcinoma (hcc) * no prior systemic therapy for hcc. previous use of herbal therapies/traditional chinese medicines with anti-cancer activity included in the label is allowed. * bclc stage b or c, and not suitable for surgical or local therapy, or has progressed following surgical and/or local therapy * at least one measurable lesion per recist v1.1 * ecog performance status of 0 or 1 * child-pugh class of a5 to b7 * adequate organ function exclusion criteria: * known hepatocholangiocarcinoma, sarcomatoid hcc, mixed cell carcinoma and lamellar cell carcinoma; other active malignant tumor except hcc within 5 years or simultaneously * moderate-to-severe ascites with clinical symptoms * history of gastrointestinal hemorrhage within 6 months prior to the start of study treatment or clear tendency of gastrointestinal hemorrhage * abdominal fistula, gastrointestinal perforation or intraperitoneal abscess within 6 months prior to the start of study treatment * known genetic or acquired hemorrhage or thrombotic tendency * thrombosis or thromboembolic event within 6 months prior to the start of study treatment * hypertension that can not be well controlled through antihypertensive drugs factors to affect oral administration * history of hepatic encephalopathy * previous or current presence of metastasis to central nervous system
black cohosh for host flashes due to androgen deprivation therapy

Conditions: Hot Flashes

Summary: this is a randomized, placebo-controlled crossover study. participants will be actively participating in the study for 6 months, and enrolled in the study for up to 1 year. during the first phase of the study, the participants will be randomized into either the placebo group or treatment group for 8 weeks following 1 week of baseline data collection (no treatment). following this first phase, a no-treatment washout period of at least 3 weeks will be implemented for all participants. after the washout period, the randomized groups will switch from treatment to placebo group, or placebo to treatment group for an additional 8 week period. hot flash frequency and severity will be documented using a daily hot flash diary and calculated using the hot flash score questionnaire. the impact on quality of life will be documented by weekly hot flash related daily interference scale (hfrdis) questionnaires.


Eligibility criteria:
inclusion criteria: * able to understand english or be wiling to use a trained interpreter * diagnosis of prostate cancer * receiving either leuprolide or degarelix,for prostate cancer treatment * currently experiencing a minimum of 3 self-reported hot flashes within a 24 hour period * eastern cooperative oncology group (ecog) performance status score \< 2 * life expectancy \>3 months. * no grade 3 or higher toxicity from prior cancer therapies unless judged by the principal investigator to be clinically irrelevant to study procedures * at least four (4) weeks following prior major surgery * serum testosterone concentration below castrate level (\< 30 ng/dl) at time of recruitment * willing to provide written informed consent for participation in the study exclusion criteria: * concurrent severe illness effecting ecog performance status or life expectancy as determined by the principal investigator * hormone refractory patients. patients taking enzalutamide or abiraterone. * active infection * psychiatric illness or social situation that would limit safety and compliance with study requirements * currently taking any pharmaceutical medications that have potential interactions with black cohosh as determined by the principal investigator * currently taking any supplements that have potential interactions with black cohosh as determined by the principal investigator * currently receiving any treatment for hot flashes or planning to initiate any treatment for hot flashes other than with study supplementation * alt, ast, or bilirubin \> 2 times their normal laboratory values in the past 3 months * inability to complete the informed consent process or adhere to the protocol treatment plan.
evaluation of new specifications (38mm) of firehawktm in the treatment of coronary heart disease

Conditions: Coronary Heart Disease

Summary: the purpose of this study is to evalute the clinical safety and effectiveness of released specification (38mm) of firehawktm sirolimus target-eluting coronary stent system.


Eligibility criteria:
inclusion criteria: 1. 18-80 years of age, males or non-pregnant women; 2. evidence of silent ischemia, stability or in patients with old myocardial infarction or unstable angina; 3. primary target lesion, in situ coronary artery disease; 4. target lesion length ≤ 60mm, target lesion diameter 2.75mm or 4.0mm (visual method); 5. the target lesion diameter stenosis ≥ 70% (visual method); 6. each target lesion implantation the same stent (firehawk stand); 7. with indications for coronary artery bypass surgery; 8. to understand the purpose of testing, voluntary and informed consent, patients undergoing invasive imaging follow-up. exclusion criteria: 1. within 72h of any acute myocardial infarction; 2. unprotected left main coronary artery disease, triple vessel lesions which need treated all; 3. severe calcified lesions that cannot be successfully expanded and distorting lesions not suitable for stent delivery; 4. artery and/or vein bypass graft lesions; 5. intracoronary implantation of any branding stents within 1 year; 6. severe congestive heart failure (nyha class iii and above), or left ventricular ejection fraction \<35% (ultrasound or left ventricular angiography); 7. preoperative renal function serum creatinine \>2.0mg/dl; 8. bleeding, active gastrointestinal ulcers, brain hemorrhage or subarachnoid hemorrhage and half year history of ischemic stroke, antiplatelet agents and would not allow an anticoagulant therapy contraindications patients undergoing antithrombotic therapy; 9. aspirin, clopidogrel, heparin, contrast agent, poly lactic acid polymer and rapamycin allergies; 10. the patient's life expectancy is less than 12 months; 11. top participated in other drug or medical device and does not meet the primary study endpoint in clinical trials time frame; 12. researchers determine patient compliance is poor, unable to complete the study in accordance with the requirements; 13. heart transplantation patients.
ixo+a in mcrc with liver-only metastases

Conditions: Metastatic Colorectal Cancer

Summary: the percentage of patients with defined unresectable metastatic disease who will benefit from a first-line treatment enabling secondary complete metastasectomy is unknown but limited. definition of optimized treatment algorithms is difficult due to very inhomogeneous patient populations. this open label, multicentre phase ii study primarily aims to assess the resection rate achievable in a selected patient population with initially unresectable metastatic disease limited to the liver only in order to evaluate feasibility, safety and efficacy with regards to secondary resection of hepatic lesions in these patients. the trial aims to enrol only patients meeting defined criteria of unresectability with regards to their hepatic lesions and will exclude patients with extrahepatic lesions in order to examine the most appropriate, highly active treatment regimen for this group of unresectable patients with the highest probability of a successful secondary metastasectomy with curative intent. the trial will be conducted in highly specialized centres with a track record of successful interdisciplinary treatment approaches in the field of metastatic colorectal cancer to allow the precise assessment of the peri-operative safety parameters as well as an evaluation of the surgical treatment approaches. the ixo regimen selected for this study has shown in a phase i/ii study promising efficacy and a favourable safety profile. bevacizumab has demonstrated a significant survival benefit in combination with chemotherapy in metastatic colorectal cancer. therefore the study will allow evaluation of its potential benefit in combination with the two most active current chemotherapy regimens in the first-line and post-operative treatment setting.


Eligibility criteria:
inclusion criteria: * primary colorectal cancer with unresectable metastatic lesion(s) * at least one measurable lesion, confirmed by ct scan * male and female patients, aged ≥ 18 years * ecog performance score of 0 or 1 (within 1 week of study treatment start) * written informed consent * adequate general condition, cardiopulmonary functions and performance status * liver metastases no initially foreseen r0 resection of all hepatic lesions, but deemed potentially resectable after response to downsizing therapy exclusion criteria: * extrahepatic metastatic disease * prior systemic or local treatment for metastatic disease, prior therapy with a biologic agent, prior adjuvant or neo-adjuvant chemotherapy, prior radiotherapy to the liver, other concurrent chemotherapy * inadequate bone marrow, liver, renal function, uncontrolled hypertension * pregnancy or lactation

Keywords: unresectable liver-only metastases in colorectal cancer